Top

Published in:

01-12-2011 | Editorial Commentary

Dosing of glucocorticosteroids in nephrotic syndrome

Authors: Otto Mehls, Peter F. Hoyer

Published in: Pediatric Nephrology | Issue 12/2011

Excerpt

Pharmacodynamic actions and molecular mechanisms of corticosteroids in patients with nephrotic syndrome (NS) are poorly understood. The role of immunosuppressive and of direct stabilizing effects on the podocyte cytoskeleton needs to be defined. Without precise knowledge of the pathogenesis, optimal dosing cannot be established. The finding of Saadeh et al. [1] that dosing of glucocorticoids per body surface area is superior to dosing per kilogram body weight (BW) in terms of reducing the recurrence rate of NS is interesting; however, an overriding effect of age cannot be ruled out. …

Saadeh SA, Baracco R, Jain A, Kapur G, Mattoo TK, Valentini RP (2011) Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol. doi:https://doi.org/10.1007/s00467-011-1961-3

Feber J, Al-Matrafi J, Farhadi E, Vaillancourt R, Wolfish N (2009) Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol 24:1027–1031CrossRefPubMed

Hodson EM, Willis NS, Craig JC (2010) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 11:CD003594

Port RE, Mehls O (2009) Pediatr Nephrol Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol 24:435–437CrossRefPubMed

Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152:357–361CrossRefPubMed

Arbeitsgemeinschaft für Pädiatrische Nephrologie (1988) Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Lancet 1(8584):830–833

Vester U, Kranz B, Zimmermann S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661–664CrossRefPubMed

Kyrieleis HA, Levtchenko EN, Wetzels JF (2007) Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 49(5):592–597CrossRefPubMed

Hoyer PF, Brodehl J (2006) Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 17:1151–1157CrossRefPubMed

10.

Elie V, Fakhoury M, Deschênes G, Jacqz-Aigrain E (2011) Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoidsglucocorticoids and epigenetic perspectives. Pediatr Nephrol. doi:https://doi.org/10.1007/s00467-011-1947-1

11.

Niaudet P (1994) Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 125:981–986CrossRefPubMed

12.

McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5:2115–2121CrossRefPubMed

13.

Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH (2011) Minimal change disease: a "two-hit" podocyte immune disorder? Pediatr Nephrol 26:645–649CrossRefPubMed

14.

Yanagida-Asanuma E, Asanuma K, Kim K, Donnelly M, Young Choi H, Hyung Chang J, Suetsugu S, Tomino Y, Takenawa T, Faul C, Mundel P (2007) Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. Am J Pathol 171:415–427CrossRefPubMedPubMedCentral

15.

Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, Kurayama R, Sekine Y, Bessho F, Takahashi S, Swiatecka-Urban A, Tryggvason K, Yan K (2007) Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 18:2554–2564CrossRefPubMed

16.

Beckmann OhJ, Bloch J, Hettgen V, Mueller J, Li L, Hoemme M, Gross ML, Penzel R, Mundel P, Schaefer F, Schmitt CP (2011) Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int 80(5):483–492. doi:https://doi.org/10.1038/ki.2011.105 CrossRefPubMed

17.

Fujii Y, Khoshnoodi J, Takenaka H, Hosoyamada M, Nakajo A, Bessho F, Kudo A, Takahashi S, Arimura Y, Yamada A, Nagasawa T, Ruotsalainen V, Tryggvason K, Lee AS, Yan K (2006) The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 69:1350–1359CrossRefPubMed

18.

Groeneweg FL, Karst H, de Kloet ER, Joëls M (2011) Rapid non-genomic effects of corticosteroids and their role in the central stress response. J Endocrinol 209:153–167CrossRefPubMed

19.

Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES (2004) Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc 1(3):235–238CrossRefPubMed

20.

Charmandari E, Kino T, Ichijo T, Chrousos GP (2008) Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 93:1563–1572CrossRefPubMedPubMedCentral

21.

Adcock IM, Barnes PJ (2008) Molecular mechanisms of corticosteroid resistance. Chest 134:394–401CrossRefPubMed

22.

van Rossum EF, van den Akker EL (2011) Glucocorticoid resistance. Endocr Dev 20:127–136CrossRefPubMed

23.

Sarna S, Hoppu K, Neuvonen PJ, Laine J, Holmberg C (1997) Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. J Clin Endocrinol Metab 82:75–77PubMed

24.

Perogamvros I, Kayahara M, Trainer PJ, Ray DW (2011) Serum regulates cortisol bioactivity by corticosteroid-binding globulin dependent and independent mechanisms, as revealed by combined bioassay and physicochemical assay approaches. Clin Endocrinol (Oxf). doi:https://doi.org/10.1111/j.1365-2265.2011.04003.x

25.

Oppl B, Kofler A, Schwarz S, Rainer J, Kofler R (2011) Establishing a sensitive and specific assay for determination of glucocorticoid bioactivity. Wien Klin Wochenschr 123(7–8):222–229CrossRefPubMed

26.

Chen Y, Burckart GJ, Shah T, Pravica V, Hutchinson IV (2009) A novel method for monitoring glucocorticoid-induced changes of the glucocorticoid receptor in kidney transplant recipients. Transpl Immunol 20:249–252CrossRefPubMed

27.

Rintamäki H, Salo HM, Vaarala O, Kolho KL (2010) New means to monitor the effect of glucocorticoid therapy in children. World J Gastroenterol 16:1104–1119CrossRefPubMedPubMedCentral

Title: Dosing of glucocorticosteroids in nephrotic syndrome
Authors: Otto Mehls
Peter F. Hoyer
Publication date: 01-12-2011
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 12/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-011-1993-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dosing of glucocorticosteroids in nephrotic syndrome

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2011

Is cellular senescence important in pediatric kidney disease?

Reviews submitted from September 1, 2010 to August 31, 2011

Evaluation of microalbuminuria in obese children and its relation to metabolic syndrome

Urinary ß2-microglobulin in very preterm neonates with chorioamnionitis

Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension

Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: a randomized trial